The 3 most recent market catalysts affecting $CTOR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 92
Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Citius Oncology (CTOR) announced its Q3 earnings, reporting an EPS of $(0.08) which was in line with analyst consensus. However, the company's sales of $1.494 million fell signific…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400M
Citius Oncology (CTOR) reported a substantial 78% quarter-over-quarter increase in new institutional accounts ordering LYMPHIR, alongside achieving near-universal payer coverage. T…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August
Citius Oncology announced the expansion of its commercial and medical affairs teams, adding 29 new professionals, to support the nationwide launch of its drug LYMPHIR by August 202…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.